anti-CD45.2 antibody product blog
Tags: Antibody; Monoclonal Antibody; CD45.2; anti-CD45.2 antibody;
The CD45.2 n/a (Catalog #MBS5305574) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse monoclonal CD45.2 antibody (biotin) reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s CD45.2 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), Immunohistochemistry (IHC).FC: <= 0.25 ug/test. Researchers should empirically determine the suitability of the CD45.2 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Mouse monoclonal CD45.2 antibody (biotin) with the following immunoassay(s):
Flow Cytometry (FC/FACS) (Surface staining of BALB/c mouse splenocytes with CD45.2 antibody (PE) (left), and (APC)-Cy7 (right). Appropriate Isotype Controls were used (open histogram). Total viable cells were used for analysis.)
Assay Information: A test is defined as the amount (ug) of antibody that will stain a cell sample in a final volume of 100 ul. Cell number should be determined empirically but can range from 10? to 10? cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Conjugate: Biotin. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD45.2 are readily searchable from our website. Different antibodies against the same target such as CD45.2 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.